In a recent article on the Jewish Journal website
(http://dtn.fm/DhxK8), doctors, dignitaries and officials representing Israel
and California convened at Cedars-Sinai Medical Center on February 8, 2016, to
witness the signing of an agreement between Israel’s Ministry of Science and
the California Institute for Regenerative Medicine (CIRM) to collaborate on
stem cell research. It follows a 2014 Memorandum of Understanding to promote
collaboration and innovation between Israel and California.
“Stem cell research is a cutting-edge field full of promise
and opportunity. Who better to forge new ground together than the State of
Israel and the State of California?” Israeli Minister of Science, Technology
and Space Ofir Akunis said in the article. “Both are hotbeds of innovation,
medical research and technological invention and have a strong commitment to
science as a means to improve the lot of all humanity … creating a brighter
future for us all.”
International Stem Cell Corp. (OTCQB: ISCO) specializes in
the therapeutic applications of human stem cells and the development and
commercialization of cell-based biomedical products. The company was the first
to develop and perfect a new class of human stem cells called parthenogenetic
stem cells, created from unfertilized human eggs. The company’s stem cells
present superior immune matching capabilities and can be used in millions of
people, regardless of sex or racial background, with minimal expectation of
immune rejection after transplantation.
Stem cells are the future of medicine. Companies like
International Stem Cell Corp. are on the front lines of this invaluable
research, constantly looking for new ways stem cells can improve our quality of
life by treating and eliminating diseases of the central nervous system (i.e.
Parkinson’s disease), the liver, and the eye. The technology is getting better
every day, and more people are coming around to at least giving it a look. The
company has an ethical and moral purpose along with the potential to capitalize
on a huge revenue stream.
The combined direct and indirect costs of Parkinson’s
disease (PD), including treatment, social security payments and lost income
from inability to work, is estimated to be nearly $25 billion per year in the
U.S. alone. Medication costs for an individual person with PD average $2,500 a
year, and therapeutic surgery can cost up to $100,000 dollars per patient.
For more information, visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
